Qazi Parvaiz Hassan

Discovery of anti-microbial and anti-tubercular molecules from Fusarium solani: an endophyte of Glycyrrhiza glabra

Glycyrrhiza glabra is a high‐value medicinal plant thriving in biodiversity rich Kashmir Himalaya. The present study was designed to explore the fungal endophytes from G. glabra as a source of bioactive molecules.

Antimicrobial investigation of selected soil actinomycetes isolated from unexplored regions of Kashmir Himalayas, India

The aim of the present study was to isolate and evaluate the antimicrobial potential of soil actinomycetes of Kashmir Himalayas. The secondary metabolites of actinomycetes are the prominent source of antibiotics. A total of 121 morphologically different actinomycete strains were isolated and screened for antimicrobial activity against various human pathogens. The ethyl acetate extract of fermented broth an actinomycete strain, identified as Streptomyces pratensis exhibited significant antimicrobial activity against Staphylococcus aureus ATCC 29213 with MIC 0.25xa0μg/ml and Mycobacterium tuberculosis Strain H37Rv with MIC 0.062xa0μg/ml. The strain S.xa0pratensis IIIM06 was grown on large scale and their broth was extracted with ethyl acetate. The extract was subjected to various chromatography techniques which led to the isolation of four compounds whose structures were established as actinomycin C1, actinomycin C2, actinomycin C3 and actiphenol on the basis of spectral data analysis. Actinomycin C1, C2 and C3 exhibited potent antimicrobial activity against S.xa0aureus as well as M.xa0tuberculosis. The isolated indigenous actinomycetes exhibited good antibacterial activity and the study reveals that IIIM06 is a promising strain and could be of great potential for industrial applications.

Novel bioactive molecules from Lentzea violacea strain AS 08 using one strain-many compounds (OSMAC) approach

A new eudesmane sesquiterpenoid (1), and a new homologue of virginiae butanolide E (2) along with butyl isobutyl phthalate (3) were isolated from, actinomycete-Lentzea violacea strain AS08 isolated from north western Himalayas by stressing on modified one strain-many compounds (OSMAC) method. The structures of the new compounds were elucidated by extensive spectroscopic analyses including 1D, 2D NMR along with HR-ESI-MS and FT-IR data. Herein, a distinctive method was added for inspecting secretory profile of the strain by quantification of extract value of cell free supernatant in different types of culture media fallowed by HPLC profiling of respective extracts, which revealed a highly altered metabolic profile of the strain and formed the base for the selection of media. The compounds 1 and 2 showed moderate activity against Gram negative (MIC ∼32-64µgml-1) in comparison to Gram positive bacterial pathogens. Compound 1 exhibited significant activity in human cancerous cell lines (IC50 ∼19.2µM).

Endophytes and Neurodegenerative Diseases: A Hope in Desperation

Neurodegeneration is progressive loss of functional and structural integrity of the central nervous system. Neurodegenerative disorders are yet without any reliable therapy because the neurons of the central nervous system have limited ability to regenerate. Current therapeutic approaches rely mainly on abrogation of symptoms and leave the dying neurons to their fate. Protective and/or rescuing treatments need to be explored fully to suppress neuronal death that will automatically alleviate the symptoms. Adequate precedent exists in literature regarding the neuroprotective activity of endophytes. Endophytes are a class of microorganisms which colonize healthy plant tissues without causing any apparent harm to the host. Chemical moieties from known endophytes have been used against many disease models including neurodegenerative diseases. There is great hope that novel bioactive molecules from newer endophytes can impede pathogenic mechanisms and progression of many diseases. In this review, we will discuss promising pharmacological or clinical relevance of endophytes against various neurodegenerative diseases.

Bioremediation: Green and Sustainable Technology for Textile Effluent Treatment

In recent decades, textile industrial sectors are getting increasing interest worldwide in global contest due to the diverse and changing world market conditions in terms of price, design, ease of handling, durability, and product safety. The increasing ecological and health concerns related to the use of large amounts of dyes (Synthetic as well as natural) in textile industries to counter the growing demands of people lead to the design, development and establishment of new dyeing strategies; and technologies in addition of reducing the load of effluents in wastewaters. Textile industrial sectors and its associated wastewaters have become an increasing cause of main sources of severe pollution worldwide. The effluents produced from these textile wet processing industries are very diverse in chemical composition, ranging from inorganic finishing agents, surfactants, chlorine compounds, salts, total phosphate to polymers and organic products. Most of the techniques used for removal of dye effluents from wastewaters were physico-chemical methods which are costly and cause an accumulation of concentrated sludge. Hence there is need to develop alternative treatments plans and strategies that are are cost effective and environmentally benign. In this paper authors review the advancements in eco-friendly and sustainable technologies used for minimizing the negative environmental impact of wastewater from textile sectors by biological and combination systems.

Streptomyces puniceus strain AS13., Production, characterization and evaluation of bioactive metabolites: A new face of dinactin as an antitumor antibiotic

A highly active actinobacterial strain isolated from untapped areas of Northwestern Himalayas and characterised as Streptomyces puniceus strain AS13 by 16S rRNA gene sequencing was selected for production of bioactive metabolites. The bioassay-guided fractionation of microbial cultured ethyl acetate extract of the strain, led to isolation of macrotetrolide compound 1 (Dinactin) and compound 2 (1-(2,4-dihydroxy-6-methylphenyl)-ethanone). Structures of the isolated compounds were elucidated by [corrected] interpretation of NMR and other spectroscopic data including HR-ESI-MS, FT-IR. These compounds are reported for first time from Streptomyces Puniceus. Compound 1 exhibited strong anti-microbial activity against all tested bacterial pathogens including Mycobacterium tuberculosis. The MIC values of compound 1 against Gram negative and Gram positive bacterial pathogens ranged between 0.019 - 0.156μgml-1 and 1μgml-1 against Mycobacterium tuberculosis H37Rv. Dinactin exhibited marked anti-tumor potential with IC50 of 1.1- 9.7μM in various human cancerous cell lines and showed least cytotoxicity (IC50∼80μM) in normal cells (HEK-293). Dinactin inhabited cellular proliferation in cancer cells, reduced their clonogenic survival as validated by clonogenic assay and also inhabited cell migration and invasion characteristics in colon cancer (HCT-116) cells. Our results expressed the antimicrobial potential of dinactin and also spotted its prospective as an antitumor antibiotic.

Bovine mastitis: An appraisal of its alternative herbal cure

Bovine mastitis is globally recognized as the most common and costly disease affecting dairy herds. The disease causes huge financial losses to dairy industries by reduced yield and milk quality, deaths and culling of affected cows and also by associated treatment costs. The disease occurs due to invasion of the mammary glands by pathogenic bacteria followed by their multiplication in the milk producing tissues. The most common treatment method available against bovine mastitis is the intra-mammary infusion of antibiotics. However, their use is associated with the problem of antimicrobial resistance. This scenario has made search for alternative treatment approaches necessary. Medicinal plants with their well-established history are an excellent natural product resource used as an alternative therapy. Antibacterial agents from plants can act as important sources of novel antibiotics, efflux pump inhibitors, compounds that target bacterial virulence or can be used in combination with existing drugs. The plants form an essential component of ethno-veterinary medicine used in the treatment of different diseases like bovine mastitis. This review article attempts to provide an overview of the different medicinal plants used in the treatment of bovine mastitis. Antimicrobial studies of these plant species and some of their isolated constituents have been reviewed in detail. It highlights the logic and precedence behind mining this important natural product resource. Our own research findings in this direction and future scope of research are also discussed briefly.

Isolation and characterization of Streptomyces tauricus from Thajiwas glacier—a new source of actinomycin-D

The aim of the present study was to isolate potent anticancer compound from actinomycetes strain SRP18 isolated from soil of high altitude region of Thajiwas glacier, Sonamarg Kashmir—India. The potential isolate SRP18 was identified as Streptomyces tauricus on the basis of 16S rDNA sequence technique. The large scale cultivation of potent strain, Streptomyces tauricus SRP18 and subsequent isolation and purification by a series of chromatographic techniques resulted in isolation of potent anticancer compound. Structure elucidation of potent compound by using various spectroscopic techniques including NMR was confirmed to be actinomycin–D. As such, this is the first report of a strain of S. tauricus capable of producing this bioactive compound. The isolated compound was evaluated for its cytotoxicity potential against four human cancer cell lines like HeLa, PC-3, THP-1, and Caco-2 and showed a potent activity with IC50 range of 4.91–7.25u2009µM.

Oscimum sanctum extract inhibits growth of Gram positive and Gram negative bacterial strains

In the present study petroleum ether, chloroform and methanolic extracts of Oscimum sanctum were prepared using soxhlet extractor. The extracts were evaluated for antibacterial activity against one Gram positive (Staphylococcus aureus) and one Gram negative (Escherichia coli) strain. The activity of the extracts was compared with the known antibacterial drugs, Oflaxacin and Penicillin G. Disc diffusion method revealed good antibacterial activity of the chloroform and methanol extracts compared to the petroleum ether extract. Methanolic extract was found to be most active against both Staphylococcus aureus and Escherichia coli bacterial strains. The zone of inhibition of methanolic extract against Staphylococcus aureus and Escherichia coli at 50u202fmg concentration was 16.0 and 18.0u202fmm, respectively. Chloroform extract also exhibited good antibacterial activity against Staphylococcus aureus and Escherichia coli bacterial strains. The zone of inhibition of chloroform extract against Staphylococcus aureus and Escherichia coli bacterial strains was 8.0 and 6.0u202fmm, respectively. The zone of inhibition of the drug Penicillin G against Escherichia coli and Staphylococcus aureus was18.0 and 17.0u202fmm, respectively. Oflaxacin showed zone of inhibition to be 19.0 and 20.0 against Escherichia coli and Staphylococcus aureus, respectively. The petroleum ether extract exhibited no activity against any of the two tested bacterial strains. These findings suggest that methanolic extract of Oscimum sanctum has anti-bacterial potential and therefore should be investigated for phytochemistry.

In vitro evaluation of dinactin, a potent microbial metabolite against Mycobacterium tuberculosis

Current long duration treatment options and the emergence of drug resistance in tuberculosis (TB) have led to renewed interest in discovery of novel anti-tubercular agents or the scaffolds exhibiting enhanced efficacy with current anti-TB drugs. Herein, dinactin, a potent bioactive macrotetrolide isolated from Streptomyces puniceus AS13, was evaluated against Mycobacterium tuberculosis H37Rv and other susceptible and drug-resistant clinical isolates of M. tuberculosis. In vitro pharmacological assays showed that dinactin is bactericidal against laboratory standard strain M. tuberculosis H37Rv (minimum inhibitory concentration [MIC] 1xa0µg/mL and minimum bactericidal concentration [MBC] 4xa0µg/mL). Dinactin also retained its activity against various clinical isolates, including multidrug-resistant strains of M. tuberculosis. Whole cell interaction assays with standard first- and second-line anti-TB drugs showed the synergistic interaction of dinactin with rifampicin or amikacin, reflecting its suitability for use in combination regimens. The killing kinetics studies of dinactin against M. tuberculosis H37Rv revealed that it has strong concentration-dependent anti-TB activity that is also dependent on time. The kill curve also showed dynamic killing capacity of dinactin as it exhibited bactericidal potential at all concentrations tested. Kill curve data demonstrated that dinactin, like isoniazid, exerts its strong tuberculocidal activity within the first two days of exposure. This evidence strongly supports further evaluation of dinactin as a new option in the treatment of TB.